Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice

Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome

(2015) L. Poekes et al.   CLINICAL SCIENCE

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis

(2015) Siddharth Singh et al.   HEPATOLOGY

Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study

(2015) Sechang Oh et al.   HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

(2015) Sungsoon Fang et al.   NATURE MEDICINE

Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice

(2015) Fahrettin Haczeyni et al.   Obesity

Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders

(2015) Stefano Fiorucci et al.   TRENDS IN MOLECULAR MEDICINE

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

(2015) Changtao Jiang et al.   Nature Communications

Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source

(2014) You-Ying Chau et al.   NATURE CELL BIOLOGY

Adipocyte dysfunction, inflammation and metabolic syndrome

(2014) Nora Klöting et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo

(2014) Takahiro Horie et al.   Scientific Reports

From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights

(2013) Samuele De Minicis et al.   CURRENT PHARMACEUTICAL DESIGN

FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS

(2013) Elena Maneschi et al.   JOURNAL OF ENDOCRINOLOGY

Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome

(2013) Derrick M. Van Rooyen et al.   JOURNAL OF HEPATOLOGY

Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype

(2013) Geoffrey C. Farrell et al.   LIVER INTERNATIONAL

NAFLD in Asia—as common and important as in the West

(2013) Geoffrey C. Farrell et al.   Nature Reviews Gastroenterology & Hepatology

Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance

(2013) Yongjie Ma et al.   PHARMACEUTICAL RESEARCH

Regulation of energy metabolism by long-chain fatty acids

(2013) Manabu T. Nakamura et al.   PROGRESS IN LIPID RESEARCH

A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice

(2012) Déborah Heydet et al.   Developmental Neurobiology

Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

(2012) Kenneth Cusi   GASTROENTEROLOGY

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

(2012) Rohit Loomba et al.   HEPATOLOGY

Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA

(2011) S. Fiorucci et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Hepatic FXR: key regulator of whole-body energy metabolism

(2011) João Soeiro Teodoro et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

(2010) Brent A. Neuschwander-Tetri   HEPATOLOGY

The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-γ and Interfering with the Wnt/β-Catenin Pathways

(2010) Mouaadh Abdelkarim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A fresh look at NASH pathogenesis. Part 1: The metabolic movers

(2010) Claire Z Larter et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease

(2010) Jayani Manchanayake et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

(2009) Amalia Gastaldelli et al.   HEPATOLOGY

Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice

(2009) Claire Z Larter et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis

(2009) A. Mencarelli et al.   JOURNAL OF IMMUNOLOGY

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes

(2008) Claire Z. Larter et al.   JOURNAL OF HEPATOLOGY